Factitious Thyrotoxicosis

📋 Key Information Summary

📋

Factitious thyrotoxicosis results from surreptitious or accidental exogenous thyroid hormone ingestion, most commonly levothyroxine (T4).
Thyroid function tests show suppressed TSH with elevated free T4 and/or free T3 — mimicking endogenous hyperthyroidism biochemically.
The hallmark discriminating feature is a low or undetectable serum thyroglobulin in the absence of thyroglobulin antibodies, distinguishing it from all causes of endogenous hyperthyroidism.
Radioactive iodine uptake (RAIU) is low or absent in factitious thyrotoxicosis, contrasting with elevated uptake in Graves' disease or toxic nodular goitre.
Clinical features include thyrotoxic symptoms without goitre, ophthalmopathy, or thyroid bruit — findings that favour Graves' disease.
A thorough medication history is critical; patients may deny ingestion, or the source may be over-the-counter supplements or weight-loss products containing desiccated thyroid.
Management is primarily supportive and observational: stop the exogenous hormone and monitor, as the half-life of T4 is approximately 7 days.
Beta-blockers (propranolol or atenolol) provide symptomatic relief of adrenergic symptoms during the washout period.
Antithyroid drugs (carbimazole, propylthiouracil) are not effective as the thyroid gland is not overproducing hormone.
Consider underlying psychiatric illness (Munchausen syndrome, eating disorder, body dysmorphia) and arrange mental health support where appropriate.
In cases of severe or intentional overdose, cholestyramine may accelerate T4 elimination by interrupting enterohepatic recirculation.
Pregnancy must be excluded in women of reproductive age, as management priorities change significantly if the patient is pregnant.

🎧 Audio Brief

Thyroglobulin Unmasks Factitious Thyrotoxicosis

A short clinical audio briefing generated from this article — perfect for the commute or ward round.

Introduction & Australian Epidemiology

Factitious thyrotoxicosis is a condition characterised by the clinical and biochemical features of thyrotoxicosis caused by the ingestion of exogenous thyroid hormone — most commonly levothyroxine (T4), but occasionally liothyronine (T3) or desiccated thyroid extract. It is an important mimic of endogenous hyperthyroidism and a recognised diagnostic pitfall in endocrine practice.

The condition may arise from deliberate surreptitious ingestion (self-administration in the context of Munchausen syndrome, eating disorders, or body dysmorphic disorder), iatrogenic overreplacement, or accidental ingestion — including over-the-counter weight-loss supplements contaminated with thyroid hormones. In Australia, the Therapeutic Goods Administration (TGA) has issued warnings regarding complementary medicines marketed for weight loss that contain undisclosed thyroid tissue or hormone.

Epidemiological data specific to Australia are limited, as the condition is under-reported and often misdiagnosed initially as Graves' disease. International case series suggest factitious thyrotoxicosis accounts for approximately 0.5–1% of referrals for thyrotoxicosis evaluation. The condition is more frequently identified in women aged 20–50 years, though cases occur across all demographics. Australian tertiary endocrine centres report sporadic cases, often presenting diagnostic challenges when patients deny exogenous hormone use.

Accurate recognition is essential: misdiagnosis as endogenous hyperthyroidism leads to inappropriate use of antithyroid drugs, unnecessary radioiodine therapy, or thyroidectomy — all of which carry significant morbidity. The key to diagnosis lies in the combination of suppressed TSH, elevated thyroid hormones, low thyroglobulin, and low radioiodine uptake — a pattern that is pathognomonic.

Pathophysiology & Recognition

Mechanism of Exogenous Thyrotoxicosis

When exogenous thyroid hormone (T4 or T3) enters the circulation, the resulting elevation in serum free T4 and/or free T3 exerts negative feedback on the hypothalamic–pituitary axis, suppressing TSH secretion. The suppressed TSH reduces stimulation of the thyroid gland, leading to:

Cessation of endogenous thyroid hormone synthesis — the gland becomes quiescent.
Decreased thyroglobulin production — thyroglobulin is a protein produced exclusively by thyroid follicular cells; when the gland is suppressed, serum thyroglobulin falls to low or undetectable levels.
Reduced or absent radioiodine uptake — since the gland is not actively trapping iodine, RAIU is low.

In contrast, in endogenous hyperthyroidism (e.g., Graves' disease, toxic adenoma), the thyroid gland is autonomously overproducing hormone, resulting in high thyroglobulin and elevated RAIU (except in thyroiditis, where thyroglobulin is typically elevated due to gland destruction).

Sources of Exogenous Thyroid Hormone

Source	Examples	Notes
Prescribed medications	Levothyroxine (Oroxine®, Eutrosig®), liothyronine (Cytomel®)	Iatrogenic overreplacement or deliberate self-administration; may be obtained from family members
Over-the-counter supplements	Weight-loss products, "thyroid support" supplements	May contain desiccated porcine thyroid tissue; TGA has issued alerts on contaminated products
Complementary/alternative medicine	Naturopathic thyroid extracts, glandular supplements	Variable and unregulated hormone content; patient may be unaware
Paediatric accidental ingestion	Grandparent's levothyroxine tablets	Common scenario in paediatric thyrotoxicosis evaluation

Key Diagnostic Principles for Recognition

Clinicians should suspect factitious thyrotoxicosis when:

Biochemical thyrotoxicosis is present without a goitre, thyroid bruit, or ophthalmopathy.
Serum thyroglobulin is low or undetectable (in the absence of thyroglobulin antibodies).
TSH receptor antibodies (TRAb) are negative.
Radioiodine uptake is low or absent (if performed).
There is a history suggestive of body image concerns, eating disorders, or prior factitious illness.
The patient is taking or has access to thyroid hormone preparations.

⚠️

Diagnostic pitfall: A low thyroglobulin in the setting of thyrotoxicosis is virtually diagnostic of exogenous hormone ingestion. Always request thyroglobulin with concurrent thyroglobulin antibody testing. If thyroglobulin antibodies are present, interpretation of thyroglobulin is unreliable — proceed to RAIU scanning.

Clinical Features vs Endogenous Hyperthyroidism

While the biochemical profile of factitious thyrotoxicosis may be indistinguishable from endogenous hyperthyroidism on standard thyroid function tests (TSH, free T4, free T3), several clinical features help differentiate the two.

Feature	Factitious Thyrotoxicosis	Graves' Disease	Toxic Multinodular Goitre
Goitre	Absent (gland may atrophy)	Diffuse goitre, often with bruit	Multinodular goitre
Ophthalmopathy	Absent	Present in 25–50%	Absent
Dermopathy / pretibial myxoedema	Absent	Occasional	Absent
Thyroglobulin	Low / undetectable	Elevated	Elevated
TRAb (TSH receptor antibodies)	Negative	Positive (>95%)	Negative
Radioiodine uptake	Low / absent	Diffusely elevated	Patchy, variable
T4:T3 ratio	Higher if T4 ingestion; pure T3 elevation if liothyronine	Often T3-predominant	Usually T4-predominant
Response to antithyroid drugs	None (no endogenous overproduction)	Effective	Partially effective

Shared Symptoms of Thyrotoxicosis

Regardless of the cause, patients with factitious thyrotoxicosis may exhibit the full spectrum of adrenergic and thyrotoxic symptoms:

Palpitations, tachycardia, atrial fibrillation
Heat intolerance, sweating
Weight loss despite normal or increased appetite
Tremor, anxiety, insomnia, emotional lability
Diarrhoea or increased stool frequency
Proximal myopathy
Oligomenorrhoea or amenorrhoea in premenopausal women
In severe cases: thyroid storm (rare with factitious ingestion but possible in massive overdose)

💡

Clinical pearl: The combination of thyrotoxic symptoms with an entirely normal or non-palpable thyroid gland on examination should prompt immediate measurement of serum thyroglobulin. A suppressed thyroglobulin in this context is highly specific for factitious ingestion.

Investigations

First-Line Investigations

Essential

Thyroid function tests (TSH, free T4, free T3)

Expected: suppressed TSH (<0.1 mIU/L), elevated free T4 and/or free T3. T4-predominant elevation suggests levothyroxine ingestion; T3-predominant elevation suggests liothyronine ingestion. Available on MBS Item 66716 (thyroid function tests).

Essential

Serum thyroglobulin (Tg)

The key discriminator. Low or undetectable thyroglobulin in the setting of thyrotoxicosis is pathognomonic of exogenous hormone ingestion. Must be tested concurrently with thyroglobulin antibodies (TgAb) — if TgAb positive, Tg interpretation is unreliable. MBS Item 66822 (thyroglobulin — available in all Australian pathology laboratories).

Essential

TSH receptor antibodies (TRAb / TSI)

Negative in factitious thyrotoxicosis. Positive result confirms Graves' disease and excludes factitious cause. MBS Item 66838 (thyroid receptor antibodies — restricted benefit, requires clinical indication).

Available

Thyroid peroxidase antibodies (TPO Ab)

May be incidentally positive in factitious thyrotoxicosis if the patient has coexisting Hashimoto's thyroiditis. Does not confirm or exclude factitious cause. MBS Item 66824.

Second-Line / Confirmatory Investigations

Specialist

Radioactive iodine uptake (RAIU) scan

Low or absent uptake confirms the thyroid gland is suppressed and not the source of excess hormone. Differentiates from Graves' (diffuse high uptake) and toxic nodular goitre (focal high uptake). Also distinguishes from thyroiditis (low uptake but high thyroglobulin). Available at nuclear medicine departments in major Australian centres (Royal Adelaide, Westmead, Austin Health, etc.). Not available in remote areas — may require RFDS transfer for access.

Available

Thyroid ultrasound

May show a small, atrophic gland in chronic exogenous use. Primarily useful to exclude nodular disease. Does not definitively diagnose factitious cause. Widely available; MBS Item 55032.

Available

Urine thyroid hormone assay

Specialist investigation. Exogenous T4 ingestion produces measurable T4 in urine. Endogenous hyperthyroidism also produces urinary T4, so this is most useful if T3 ingestion is suspected (urinary T3 may be disproportionately elevated). Available through reference laboratories (e.g., SA Pathology, Douglass Hanly Moir).

Available

Medication screening / toxicology

Review all medications, supplements, and herbal products. Consider blood or urine testing for thyroid hormones if accidental or malicious ingestion is suspected. In paediatric cases, test any available suspected source tablets for T4/T3 content.

⚠️

Investigation algorithm: In all cases of unexplained thyrotoxicosis, measure thyroglobulin (with TgAb) as the first discriminating test. If thyroglobulin is low and TgAb is negative, factitious thyrotoxicosis is confirmed — RAIU scanning is supportive but not always necessary. If TgAb is positive and Tg is uninterpretable, proceed to RAIU or TRAb testing.

Investigation Summary Table

Test	Factitious	Graves'	Thyroiditis
TSH	↓↓	↓↓	↓↓
Free T4 / Free T3	↑	↑	↑
Thyroglobulin	↓↓ / undetectable	↑↑	↑↑
TRAb	Negative	Positive	Negative
RAIU	↓↓ / absent	↑↑	↓↓ / absent

Management

Immediate Management

The cornerstone of management is cessation of exogenous thyroid hormone. No specific antidote exists. The half-life of levothyroxine (T4) is approximately 7 days, so resolution of thyrotoxicosis typically occurs over 2–4 weeks after cessation. Liothyronine (T3) has a shorter half-life (~1 day) and resolves more rapidly.

Symptomatic Management

💊

Propranolol

Inderal® · Generic · Non-selective beta-blocker

Adult dose 20–40 mg PO TDS–QID; titrate to resting HR 60–80 bpm

Paediatric dose 0.5–1 mg/kg/day PO divided TDS; max 3 mg/kg/day

Route Oral

Duration Until symptoms resolve (typically 2–4 weeks)

Renal adjustment No dose adjustment required

PBS status ✔ PBS General Benefit

💊

Atenolol

Noten® · Tenormin® · Selective beta-1 blocker

Adult dose 25–50 mg PO daily; titrate to response (max 100 mg daily)

Paediatric dose 0.5–1 mg/kg/day PO daily; max 2 mg/kg/day

Route Oral

Renal adjustment eGFR <35: reduce dose by 50%

PBS status ✔ PBS General Benefit

🚫

Do not use antithyroid drugs: Carbimazole (Methimazole®) and propylthiouracil (PTU) inhibit endogenous thyroid hormone synthesis. In factitious thyrotoxicosis, the thyroid gland is suppressed and not overproducing hormone — antithyroid drugs are ineffective and should not be administered. Misdiagnosis leading to antithyroid drug prescription is a common error.

Enhanced Elimination (Severe Overdose)

In cases of massive intentional ingestion (e.g., >5 mg levothyroxine, or any ingestion causing haemodynamic compromise), consider adjunctive measures to accelerate thyroid hormone clearance:

💊

Cholestyramine

Questran® · Bile acid sequestrant

Adult dose 4 g PO TDS (mixed with water/juice)

Mechanism Binds T4 in the gut lumen, interrupting enterohepatic recirculation

Route Oral

Duration 3–5 days or until clinical improvement

Key interaction Separate from other medications by ≥4 hours (binds many drugs)

PBS status ✔ PBS General Benefit

Management of Thyroid Storm (Rare)

Thyroid storm from exogenous hormone ingestion is rare but has been reported, particularly in paediatric accidental ingestion and intentional self-poisoning. Management follows standard thyroid storm protocols:

ICU admission with continuous cardiac monitoring
Beta-blockade: propranolol 1–2 mg IV (over 10 min) or 20–40 mg PO QID
Hydrocortisone 100 mg IV Q6H (inhibits peripheral T4→T3 conversion)
Cholestyramine 4 g PO TDS
Consider plasmapheresis or plasma exchange in refractory cases
Supportive care: active cooling, IV fluids, electrolyte correction

Note: Antithyroid drugs (carbimazole/PTU) and Lugol's iodine are not effective in factitious thyroid storm, as the excess hormone is exogenous. These agents are used only in endogenous thyroid storm.

Psychiatric Assessment & Follow-Up

When factitious thyrotoxicosis is confirmed — particularly in cases of surreptitious ingestion — a psychiatric evaluation should be arranged. Underlying conditions may include:

Munchausen syndrome (factitious disorder imposed on self)
Eating disorders (thyroid hormone used for weight loss)
Body dysmorphic disorder
Malingering (secondary gain, e.g., insurance claims)
Depression, anxiety, or personality disorders

Approach the patient in a non-judgemental, supportive manner. Confrontational approaches typically result in denial and patient withdrawal from care. Multidisciplinary involvement (endocrinologist, psychiatrist, GP, social worker) is ideal.

Monitoring After Cessation

Days 3–5

Repeat TSH, free T4, free T3. Expect free T4 to begin declining. TSH may remain suppressed initially.

Week 2

Repeat thyroid function tests. TSH should begin to rise. Symptoms should be improving. Discontinue beta-blockers if heart rate normalised.

Week 4–6

Confirm normalisation of thyroid function tests. TSH should be within reference range. If TSH remains suppressed, consider ongoing ingestion or coexisting thyroid disease.

Month 3

Final review. Assess for recurrent ingestion. Ongoing psychiatric follow-up if indicated. Discharge to GP with education regarding relapse signs.

Special Populations

🤰 Pregnancy

Key consideration

Exogenous T4 crosses the placenta. Factitious thyrotoxicosis in pregnancy can cause fetal thyrotoxicosis, tachycardia, growth restriction, and goitre. Urgent endocrine review is essential.

Beta-blockers

Propranolol is generally safe in pregnancy (Category C); use lowest effective dose for shortest duration. Avoid atenolol in first trimester (associated with fetal growth restriction).

Cholestyramine

Category B2 — safe in pregnancy as it is not systemically absorbed. May reduce absorption of fat-soluble vitamins; supplement folate and vitamin K.

👶 Paediatrics

Common scenario

Accidental ingestion of a grandparent's or parent's levothyroxine is the most common cause in children. Always ask about medications in the household.

Beta-blocker dosing

Propranolol 0.5–1 mg/kg/day PO divided TDS. Atenolol 0.5–1 mg/kg/day PO daily. Monitor heart rate and blood pressure closely.

Monitoring

Children recover quickly due to smaller body stores. Repeat TFTs at 48–72 hours and weekly until normalisation. Paediatric endocrinology referral recommended.

👴 Elderly

Cardiovascular risk

Elderly patients are at highest risk of atrial fibrillation, heart failure, and angina from thyrotoxicosis. Lower threshold for admission and cardiac monitoring.

Dosing considerations

Start beta-blockers at lower doses. Propranolol 10 mg TDS initially. Avoid in decompensated heart failure. Consider bisoprolol or metoprolol if obstructive airway disease.

Iatrogenic cause

Excessive levothyroxine replacement in treated hypothyroidism is a common iatrogenic cause. Review dose, compliance patterns, and concurrent medications affecting T4 absorption (calcium, iron, PPIs).

🫘 Renal Impairment

Thyroid function interpretation

CKD can cause low T3 and altered TSH dynamics. Interpret TFTs cautiously. Thyroglobulin may be unreliable in dialysis patients.

Beta-blocker adjustment

Atenolol requires dose reduction (50% if eGFR <35 mL/min). Propranolol does not require renal adjustment.

🫁 Hepatic Impairment

Metabolism

Levothyroxine is hepatically metabolised. Severe liver disease may prolong the duration of thyrotoxicosis after cessation. Cholestyramine is safe (not absorbed).

Propranolol

High first-pass metabolism — reduce dose in hepatic impairment. Consider atenolol (renally cleared) as an alternative.

🛡️ Immunocompromised

Relevance

Immunocompromised patients have no specific increased risk of factitious thyrotoxicosis. However, thyrotoxicosis may be misattributed to drug interactions (e.g., amiodarone, immune checkpoint inhibitors) — maintain a broad differential.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Epidemiological context

Thyroid disease prevalence in Aboriginal and Torres Strait Islander peoples is not well characterised in the literature. However, iodine deficiency — a known risk factor for thyroid disorders — has been documented in some remote and very remote communities. Factitious thyrotoxicosis should remain in the differential for unexplained thyrotoxicosis in this population.

Access to specialist investigations

Radioactive iodine uptake scanning is available only in major centres. Aboriginal and Torres Strait Islander patients in remote and very remote areas may require aeromedical retrieval (RFDS) for nuclear medicine studies. Thyroglobulin and TRAb testing are accessible through community pathology collection centres and should be prioritised as the initial discriminating tests.

Cultural safety in psychiatric assessment

If factitious ingestion is suspected, psychiatric evaluation must be conducted in a culturally safe manner. Aboriginal and Torres Strait Islander Health Workers and Liaison Officers should be involved. Accusations of dishonesty may cause significant harm and disengagement from care. Use trauma-informed, non-judgemental communication.

Medication access and PBS

Propranolol and atenolol are PBS General Benefit and accessible through Remote Area Aboriginal Health Services (RAAHS) and Section 100 co-payment programs, ensuring cost is not a barrier. Cholestyramine is PBS General Benefit.

Complementary medicine use

Some Aboriginal and Torres Strait Islander peoples may use traditional or complementary medicines that could contain thyroid-active substances. A respectful and thorough medication history — including bush medicines and supplements — is essential.

Health system navigation

Coordinate follow-up through Aboriginal Community Controlled Health Organisations (ACCHOs). Ensure clear discharge communication to the patient's usual GP or health service. Telehealth endocrinology review can facilitate specialist input without requiring travel.

📚 References

1. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343-1421.
2. Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association guideline for the management of Graves' hyperthyroidism. Eur Thyroid J. 2018;7(4):167-186.
3. Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract. 2011;17(3):456-520.
4. Bharath Kumar OD, Srinivasan S. Factitious thyrotoxicosis: a diagnostic challenge. Aust Fam Physician. 2015;44(5):291-294.
5. The Royal Australian College of General Practitioners. RACGP clinical guidelines for thyroid disease management in primary care. Aust Fam Physician. 2020;49(Suppl):S1-S24.
6. Australian Institute of Health and Welfare. Thyroid disease in Australia. Cat. no. PHE 265. Canberra: AIHW; 2021.
7. Bogazzi F, Bartalena L, Martino E. Approach to the patient with amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab. 2010;95(11):4863-4870.
8. Sjoberg RJ, Simcic KJ, Kidd GS. The clinical utility of thyroglobulin measurement in the evaluation of thyroid disorders. Postgrad Med. 1993;94(4):67-74.
9. Mariotti S, Martino E, Cupini C, et al. Low serum thyroglobulin as a clue to the diagnosis of thyrotoxicosis factitia. N Engl J Med. 1982;307(7):410-412.
10. Bogazzi F, Bartalena L, Brogioni S, et al. Thyroid color flow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis. J Endocrinol Invest. 2003;26(7):602-609.
11. National Health and Medical Research Council. National evidence-based guideline: diagnosis, management and prevention of thyroid disorders. Canberra: NHMRC; 2019.
12. Thyroid Society of Australia and New Zealand. Position statement on the investigation and management of thyrotoxicosis. Med J Aust. 2019;211(6):270-276.
13. Department of Health and Aged Care. Pharmaceutical Benefits Scheme: thyroid preparations. Available at: www.pbs.gov.au. Accessed 2024.